Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct 5:11:1756286418803248.
doi: 10.1177/1756286418803248. eCollection 2018.

Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting

Philipp Albrecht  1 , Ingrid Kristine Bjørnå  2 , David Brassat  3 , Rachel Farrell  4 , Peter Feys  5 , Jeremy Hobart  6 , Raymond Hupperts  7 , Michael Linnebank  8 , Jožef Magdič  9 , Celia Oreja-Guevara  10 , Carlo Pozzilli  11 , Antonio Vasco Salgado  12 , Tjalf Ziemssen  13
Affiliations
Review

Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting

Philipp Albrecht et al. Ther Adv Neurol Disord. .

Abstract

Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple sclerosis (MS), having been shown to produce a clinically meaningful improvement in walking ability in the subset of MS patients with Expanded Disability Status Scale 4-7. Recent responder subgroup analyses in the phase III ENHANCE study show a large effect size in terms of an increase of 20.58 points on the patient-reported 12-item MS Walking Scale in the 43% of patients classified as responders to PR-fampridine, corresponding to a standardized response mean of 1.68. Use of PR-fampridine in clinical practice varies across Europe, depending partly on whether it is reimbursed. A group of European MS experts met in June 2017 to discuss their experience with using PR-fampridine, including their views on the patient population for treatment, assessment of treatment response, re-testing and re-treatment, and stopping criteria. This article summarizes the experts' opinions on how PR-fampridine can be used in real-world clinical practice to optimize the benefits to people with MS with impaired walking ability.

Keywords: multiple sclerosis; prolonged-release fampridine; real-world experience; treatment response; walking ability.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Philipp Albrecht has received research grants from Allgergan, Biogen, Ipsen, Merz Pharmaceuticals, Novartis, Roche and Teva, and travel/accommodation/meetingexpenses/speaker honoraria from Allergan, Bayer Healthcare, Biogen, Ipsen, Merck, Merz Pharmaceuticals, Novartis and Teva. Ingrid Kristine Bjørnå has received compensation for travel and advisory boards, speaker honoraria and consultant fees from Merck, Biogen, Sanofi-Genzyme, Bayer, Novartis, Roche and Teva, as well as support for participation in clinical trials in multiples sclerosis sponsored by Schering, Serono, Biogen, Novartis, Genzyme and Roche. David Brassat has received travel and lecture fees from Bayer, Biogen, Merck, Novartis Pharma, Roche and Sanofi-Genzyme. Rachel Farrell has received speaker honoraria, compensation for advisory roles, hospitality and educational grants from Merck, Canbex Pharmaceuticals Ltd, Allergan, Merz, TEVA, Novartis, Genzyme and Biogen. Dr Farrell’s current research activity is supported by the NIHR Biomedical Research Centre UCLH. Peter Feys has received consulting/advisory board fees for Biogen and Novartis; speaker fees from Excemed; he is an editorial board member for Multiple Sclerosis Journal. Jeremy Hobart has received consulting/advisor fees/honoraria/support for clinical service or research from Acorda, Biogen, Global Blood Therapeutics, F. Hoffmann-La Roche, LORA group, Merck Serono, Novartis, Sanofi-Genzyme, Tigercat Pharma, and Vantia. Raymond Hupperts has received institutional research grants from Merck and Biogen, patient care support from Biogen, Merck and Sanofi-Genzyme, and honoraria for SC memberships and speaking fees from Merck, Biogen and Sanofi-Genzyme. Michael Linnebank has received compensation for advisory boards and speaker honoraria from Almirall, Bayer, Biogen, Merck, Novartis, Sanofi-Genzyme, and Teva. Jožef Magdič has received compensation for advisory boards and speaker honoraria from Bayer, Biogen, Merck, Novartis, Roche, Sanofi-Genzyme, Teva, AstraZeneca, Boehringer Ingelheim, Medis and Krka. Celia Oreja-Guevara has received compensation for advisory boards and speaker honoraria from Almirall, Biogen, Sanofi-Genzyme, Roche, Merck, Novartis and Teva. Carlo Pozzilli has received consultant fees from Actelion, Biogen, Genzyme, Merck Serono, Novartis, and Teva Neuroscience, and grant or research support from Biogen, Merck Serono, Novartis, and Teva Neuroscience. Antonio Vasco Salgado has received financial fees from Biogen, Novartis, Merck Serono, Sanofi and Roche. Tjalf Ziemssen has received compensation for consulting services from Almirall, Biogen, Bayer, Merck, Novartis, Roche, Sanofi and Teva, and has received research support from Bayer, Biogen Idec, the Hertie Foundation, the Roland Ernst Foundation, the German Diabetes Foundation, Biogen, Merck, Novartis, Teva and Sanofi.

References

    1. Souza A, Kelleher A, Cooper R, et al. Multiple sclerosis and mobility-related assistive technology: systematic review of literature. J Rehabil Res Dev 2010; 47: 213–223. - PubMed
    1. Kister I, Chamot E, Salter AR, et al. Disability in multiple sclerosis: a reference for patients and clinicians. Neurology 2013; 80: 1018–1024. - PMC - PubMed
    1. Sutliff MH. Contribution of impaired mobility to patient burden in multiple sclerosis. Curr Med Res Opin 2010; 26: 109–119. - PubMed
    1. Heesen C, Böhm J, Reich C, et al. Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Mult Scler 2008; 14: 988–991. - PubMed
    1. Fampyra 10 mg prolonged-release tablets SmPC [Internet]. Medicines.org.uk; 2018. Fampyra, https://www.medicines.org.uk/emc/medicine/25003 (2018, 11 August 2018).